Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping (ANKE)

Heinrich-Heine University, Duesseldorf

Status: Completed

Conditions: Cardiotoxicity; Breast Cancer; Myocardial Damage

Treatments: Diagnostic Test: Cardiac MRI and echocardiography, laboratory parameters

Study type: Interventional

Funder types: Other

Identifiers

NCT03940625

15-002

Details and patient eligibility

About

Anthracyclines (e.g. Doxorubicin) are an important and highly effective chemotherapeutic. They are used in various tumor entities and are established for breast cancer treatment. The most significant prognostic side effect is cardiotoxicity, which occurs in up to 50 patients. Female gender must be considered an independent risk factor for the incidence and severity of associated heart failure. The aim of this study is to demonstrate that dose-dependent anthracycline-induced cardiotoxicity has a measurable effect on T2 mapping on MRI. The second aim is to demonstrate if the combination of diastolic strain (echo and MRI) and T2 mapping can detect earlier anthracycline-induced myocardial damage than via the established method of the echocardiographic measurement of LV-EF and the conventional quantification of diastolic function.

Full description

In order to answer the question, patients with breast cancer, who will undergo a chemotherapeutic treatment with antracycline, will be examined before chemotherapy (including cmr and echocardiography) and after chemotherapy at different times within one year.

Enrollment: 69 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Planned therapy with an anthracycline and at least 1 year follow up
• >18 years of age
• written informed consent

Exclusion criteria

• prior cardiovascular disease
• diabetes mellitus
• previous therapy with anthracyclines

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)